Background/Aims Given the increase in prevalence of metabolic diseases, we investigated their long-term impacts on the outcomes of chronic hepatitis B (CHB) patients receiving nucleos(t)ide analogue (NA) treatment.
Methods We analyzed data from CHB patients for whom initiated NA treatment from 30 centers. We balanced patient characteristics with and without metabolic disease (diabetes, obesity, dyslipidemia, and hypertension) via propensity-score matching (PSM) to evaluate adverse outcomes.
Results The study included 4,500 patients. PSM yielded 909 pairs of patients with balanced characteristics. When stratified by the number of metabolic diseases, only patients with ≥2 metabolic diseases had an increased cumulative incidence of cirrhosis and overall death. However, when stratified by the presence of diabetes (regardless of the presence or number of other metabolic diseases), patients with diabetes (versus those without) had a significantly higher cumulative incidence of all outcomes: cirrhosis (P=0.009), hepatocellular carcinoma (HCC, P=0.023), and overall, liver-related, and non-liver-related death (P<0.001, P=0.026 and P<0.001, respectively). Having ≥2 metabolic diseases was associated with cirrhosis, overall death, and non-liver-related death but not HCC or liver-related death, while diabetes was significantly associated with a higher risk of all outcomes: cirrhosis (hazard ratio [HR]=3.75, P=0.004), HCC (HR=2.02, P=0.020), and overall, liver-related, and non-liver-related death (HR=2.53, P<0.001; HR=2.65, P=0.016; HR=2.38, P<0.001).
Conclusions Having two or more metabolic diseases was associated with a higher risk of cirrhosis, overall death, and non-liver-related death, but having diabetes as a single metabolic disease was significantly associated with all adverse outcomes including cirrhosis, HCC, and overall, liver-related, and non-liver-related death.
Citations
Citations to this article as recorded by
Type 2 diabetes mellitus as an independent predictor of significant fibrosis in treatment-naïve chronic hepatitis B patients with concurrent hepatic steatosis Jie Li, Liang Xu, Fajuan Rui, Sally Tran, Pei-Chien Tsai, Youwen Tan, Hidenori Toyoda, Qing-Lei Zeng, Huy Trinh, Yao-Chun Hsu, Tsunamasa Watanabe, Hiroshi Abe, Hiroyuki Motoyama, Yoko Yoshimaru, Takanori Suzuki, Taeang Arai, Masanori Atsukawa, Phillip Vut Hepatology.2026; 83(5): 1273. CrossRef
Advancing metabolic risk profiling in chronic hepatitis B: Reply to correspondence on “Metabolic health in antiviral era of chronic hepatitis B” Shang-Chin Huang, Jia-Horng Kao Clinical and Molecular Hepatology.2026; 32(1): e117. CrossRef
Metabolic health in antiviral era of chronic hepatitis B: Editorial on “Impacts of metabolic syndrome diseases on long-term outcomes of chronic hepatitis B patients treated with nucleos(t)ide analogues” Shang-Chin Huang, Jia-Horng Kao Clinical and Molecular Hepatology.2026; 32(1): 423. CrossRef
Diagnosis and management of metabolic dysfunction-associated steatohepatitis in patients with chronic hepatitis B infection Talal K Bhatti, Joseph K Lim World Journal of Gastroenterology.2026;[Epub] CrossRef
Diabetes Impairs the Virological Response in Patients with Chronic Hepatitis B: Glycemic Control as a Key Modifiable Risk Factor Aoyi Li, Yan Han, Guanglin Xiao, Zhiling Deng, Chaojing Wen, Ke Qiu, Taiyu He, Hong Ren Journal of Clinical Medicine.2026; 15(5): 1826. CrossRef
Antiviral Therapy Reduces Hepatocellular Carcinoma and Cirrhosis Risk in Chinese Chronic Hepatitis B Patients With Mildly Elevated Alanine Aminotransferase Jian Wang, Zhiyi Zhang, Li Zhu, Tao Fan, Ye Xiong, Shaoqiu Zhang, Chao Jiang, Shengxia Yin, Xin Tong, Juan Xia, Xiaomin Yan, Renling Yao, Yu Shi, Xingxiang Liu, Chuanwu Zhu, Chao Wu, Rui Huang Clinical Gastroenterology and Hepatology.2026;[Epub] CrossRef
Steatosis paradox: Unraveling pathways of suppressive effect of hepatic steatosis on hepatitis B virus Shang-Chin Huang, Jia-Horng Kao Biomedical Journal.2026; 49(3): 100969. CrossRef
Impact of Cardiometabolic Risk Factors and Steatotic Liver Disease on Liver‐Related Outcomes in Patients With Chronic Hepatitis C After Curative Antiviral Therapy Chung‐Feng Huang, Yi‐Hung Lin, Pei‐Chien Tsai, Ming‐Lun Yeh, Chih‐Wen Wang, Tyng‐Yuan Jang, Po‐Cheng Liang, Yu‐Ju Wei, Nai‐Jen Hou, Ming‐Yen Hsieh, Chao‐Kuan Huang, Tzu‐Chun Lin, Jee‐Fu Huang, Chia‐Yen Dai, Wan‐Long Chuang, Ming‐Lung Yu The Kaohsiung Journal of Medical Sciences.2026;[Epub] CrossRef
Absence of steatosis combined with cardiometabolic risk factors confers the highest hepatocellular carcinoma risk in treated chronic hepatitis B Hung-Wei Wang, Hsueh-Chou Lai, Wei-Fan Hsu, Sheng-Hung Chen, Yi-Chun Kuo, Cheng-Yuan Peng Annals of Medicine.2026;[Epub] CrossRef
Diagnosing and defining MASLD in people living with chronic hepatitis B Emily Martyn, Alejandro Arenas-Pinto, Richard Gilson, Nomathemba Chandiwana, Stuart Flanagan, Douglas MacDonald, Emmanuel A. Tsochatzis, W. D. Francois Venter, Jennifer Manne-Goehler, Philippa C. Matthews Communications Medicine.2026;[Epub] CrossRef
The Chronic Hepatitis B and Metabolic Dysfunction-Associated Steatotic Liver Disease Paradox: Friend or Foe? Shang-Chin Huang, Tai-Chung Tseng Gut and Liver.2026; 20(3): 350. CrossRef
Insulin Resistance and Hepatocellular Carcinoma Development in Chronic Hepatitis B Patients Under Antiviral Therapy Dong Hyun Sinn, Kyung-Ah Kim, Jung Il Lee, Geum-Youn Gwak Journal of Korean Medical Science.2026;[Epub] CrossRef
Efficacy and Safety of Switching from Entecavir to Tenofovir Alafenamide in Chronic Hepatitis B: A Multicenter Randomized Trial in Korea Hyunjae Shin, Moon Haeng Hur, Yang Hyun Baek, Chun Kyon Lee, Yong Kyun Cho, June Sung Lee, Jae Yoon Jeong, Yong Jin Jung, Ja Kyung Kim, Moon Young Kim, Yeon Seok Seo, Woo Jin Chung, Moon Soo Koh, Jeong-Han Kim, Yun Bin Lee, Eun Ju Cho, Jeong-Hoon Lee, Su Gut and Liver.2026; 20(4): 636. CrossRef
Comparable Predictive Performance of Non‐VCTE–Based Machine Learning Model for HBV‐Infected Hepatocellular Carcinoma Risk Hahn Yi, Hye Won Lee, Jae Il Shin, Hyung Woong Lee, Tae Seop Lim, Beom Kyung Kim, Namkug Kim Journal of Gastroenterology and Hepatology.2026;[Epub] CrossRef
Differential HCC risk among HBV indeterminate types at baseline and by phase transition Rui Huang, Huy N Trinh, Satoshi Yasuda, Angela Chau, Mayumi Maeda, Ai-Thien Do, Daniel Q Huang, Takanori Ito, Takashi Honda, Masatoshi Ishigami, Ritsuzo Kozuka, Carmen Monica Preda, Cheng-Hao Tseng, Sebastián Marciano, Pei-Chien Tsai, Dong Hyun Lee, Chris Gut.2025; 74(11): 1873. CrossRef
Incidence and determinants of achieving HBsAg <100 IU/mL in HBeAg-negative CHB patients with nucleos(t)ide analogue treatment Jian Wang, Tao Fan, Zhiyi Zhang, Li Zhu, Shaoqiu Zhang, Ye Xiong, Chun Shan, Chao Jiang, Shengxia Yin, Xin Tong, Renling Yao, Juan Xia, Xiaomin Yan, Yu Shi, Yuxin Chen, Xingxiang Liu, Huali Wang, Haixia Zhang, Chuanwu Zhu, Qun Zhang, Chao Wu, Rui Huang Emerging Microbes & Infections.2025;[Epub] CrossRef
Impact of metabolic dysfunction on treatment responses to nucleos(t)ide analogues in chronic hepatitis B: a retrospective multi-center REAL-B cohort study Rui Huang, Dae Won Jun, Hidenori Toyoda, Yao-Chun Hsu, Huy Trinh, Akito Nozaki, Toru Ishikawa, Tsunamasa Watanabe, Haruki Uojima, Daniel Q. Huang, Takashi Honda, Yasuhito Tanaka, Philip Vutien, Sebastián Marciano, Hiroshi Abe, Masaru Enomoto, Masanori Ats eClinicalMedicine.2025; 87: 103407. CrossRef
Aspirin Use and Risk of HCC and Gastrointestinal Bleeding in Patients With HBV‐Related Cirrhosis: A Landmark Analysis Mi Na Kim, Geun U. Park, Seng Chan You, Jae Seung Lee, Hye Won Lee, Beom Kyung Kim, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn Journal of Gastroenterology and Hepatology.2025; 40(11): 2750. CrossRef
Multifunctional Metal Composite Hydrogels for Diabetic Wound Therapy Shengnan Zhang, Hui Gao, Kevin H. Mayo, Jingang Mo, Le Deng Gels.2025; 11(12): 960. CrossRef
Vy H. Nguyen, Isaac Le, Audrey Ha, Richard Hieu Le, Nicholas Ajit Rouillard, Ashley Fong, Surya Gudapati, Jung Eun Park, Mayumi Maeda, Scott Barnett, Ramsey Cheung, Mindie H. Nguyen
Clin Mol Hepatol 2023;29(4):1002-1012. Published online September 11, 2023
Background/Aims Understanding of nonalcoholic fatty liver disease (NAFLD) continues to expand, but the relationship between race and ethnicity and NAFLD outside the use of cross-sectional data is lacking. Using longitudinal data, we investigated the role of race and ethnicity in adverse outcomes in NAFLD patients. Methods: Patients with NAFLD confirmed by imaging via manual chart review from any clinics at Stanford University Medical Center (1995–2021) were included. Primary study outcomes were incidence of liver events and mortality (overall and non-liver related). Results: The study included 9,340 NAFLD patients: White (44.1%), Black (2.29%), Hispanic (27.9%), and Asian (25.7%) patients. For liver events, the cumulative 5-year incidence was highest among White (19.1%) patients, lowest among Black (7.9%) patients, and similar among Asian and Hispanic patients (~15%). The 5-year and 10-year cumulative overall mortality was highest for Black patients (9.2% and 15.0%, respectively, vs. 2.5–3.5% and 4.3–7.3% in other groups) as well as for non-liver mortality. On multivariable regression analysis, compared to White patients, only Asian group was associated with lower liver-related outcomes (aHR: 0.83, P=0.027), while Black patients were at more than two times higher risk of both non-liver related (aHR: 2.35, P=0.010) and overall mortality (aHR: 2.13, P=0.022) as well as Hispanic patients (overall mortality: aHR: 1.44, P=0.022).Conclusions: Compared to White patients, Black patients with NAFLD were at the highest risk for overall and non-liver-related mortality, followed by Hispanic patients with Asian patients at the lowest risk for all adverse outcomes. Culturally sensitive and appropriate programs may be needed for more successful interventions.
Citations
Citations to this article as recorded by
Comparison of diagnostic criteria for fatty liver disease in assessing cardiac dysfunction: a cross-sectional study Yun Kyung Cho, Myung Jin Kim, Eun Hee Kim, Min Jung Lee, Hyo-Jung Nam, Woo Je Lee, Hong-Kyu Kim, Chang Hee Jung Hepatology International.2026; 20(1): 81. CrossRef
Comment on “Comparison of diagnostic criteria for fatty liver disease in assessing cardiac dysfunction: a cross-sectional study” Bin Cao, Zhenxing Deng, Ming Ouyang Hepatology International.2026; 20(4): 1237. CrossRef
Ethnic disparities in metabolic dysfunction-associated steatotic liver disease and clinical outcomes Yusuke Miyatani, Aoi Ogawa, Tomoki Sempokuya, Chuong Tran, Davis James, Todd Seto, Cecilia Shikuma, Scott K. Kuwada Frontiers in Endocrinology.2026;[Epub] CrossRef
The Role of Race and Ethnicity in the Response to Metabolic Dysfunction-Associated Steatotic Liver Disease Treatment: A Review Aoun Laurence, Shruti M. Gandhi, Eric S. Nylen, Sabyasachi Sen Endocrine Practice.2026; 32(6): 1001. CrossRef
Differential Mortality Risk by Age in Males and Females With Steatotic Liver Disease Taotao Yan, Nicholas Chien, Vy H. Nguyen, Isaac Le, Surya Teja Gudapati, Angela Chau, Xinrong Zhang, Scott Barnett, Sovann Linden, Linda Henry, Ramsey Cheung, Mindie H. Nguyen MedComm.2026;[Epub] CrossRef
Association of food insecurity with metabolic dysfunction-associated steatotic liver disease by sex and race/ethnicity Meng-Hua Tao, Chun-Hui Lin, Jialiang Liu, Weiwen Chai, Sheri Trudeau, Humberto C. Gonzalez, Mei Lu, Stuart C. Gordon European Journal of Nutrition.2026;[Epub] CrossRef
MELD and the Risk of Mortality Between Black and White Patients with Advanced Fibrosis Michael L. Attanasi, Mathew J. Gregoski, Don C. Rockey Digestive Diseases and Sciences.2026;[Epub] CrossRef
Meta‐Analysis: Global Prevalence and Mortality of Cirrhosis in Metabolic Dysfunction‐Associated Steatotic Liver Disease Soroor Owrangi, James M. Paik, Pegah Golabi, Leyla de Avila, Ryuki Hashida, Ariana Nader, Annette Paik, Linda Henry, Zobair M. Younossi Alimentary Pharmacology & Therapeutics.2025; 61(3): 433. CrossRef
Statin use and liver-related prognosis among patients with MASLD Byungyoon Yun, Heejoo Park, Jian Lee, Beom Kyung Kim, Jin-Ha Yoon JHEP Reports.2025; 7(4): 101313. CrossRef
Ethnic differences in metabolic and histologic features among White, Hispanic, Black and Asian patients with metabolic-associated Steatotic liver disease: A network meta-analysis Limin Lin, Jiaming Lai, Ling Luo, Junzhao Ye, Bihui Zhong Annals of Hepatology.2025; 30(2): 101780. CrossRef
Representation of Sex, Race and Ethnicity in MASH Randomised Controlled Trials: A Systematic Review and Meta‐Analysis Matheus Souza, Lubna Al‐Sharif, Ivanna Diaz, Samira Mohamad Khalil, Xiu‐He Lv, Alessandro Mantovani, Cristiane Alves Villela‐Nogueira Liver International.2025;[Epub] CrossRef
Differential Characteristics and Survival Outcomes of Patients With Cirrhosis According to Underlying Liver Aetiology Yu Shi, Nicholas Chien, Ashley Fong, Vy H. Nguyen, Surya Teja Gudapati, Angela Chau, Sally Tran, Linda Henry, Ramsey Cheung, Changqing Zhao, Minjuan Jin, Mindie H. Nguyen Alimentary Pharmacology & Therapeutics.2025; 61(10): 1622. CrossRef
Correspondence to letter to the editor 2 on “Evolutionary changes in metabolic dysfunction-associated steatotic liver disease and risk of hepatocellular carcinoma: A nationwide cohort study” Seogsong Jeong, Won Kim, Sang Min Park Clinical and Molecular Hepatology.2025; 31(2): e210. CrossRef
Racial and Ethnic Disparities in NAFLD: Harnessing Epigenetic and Gut Microbiota Pathways for Targeted Therapeutic Approaches Mohamed Zaiou, Olivier Joubert Biomolecules.2025; 15(5): 669. CrossRef
Young Adults With Metabolic Dysfunction–Associated Steatotic Liver Disease Have an Increased Risk of Early-Onset Cancer: A Nationwide Cohort Study Differentiating the Risk of 23 Site-Specific Cancers Joon Ho Moon, Seogsong Jeong, Heejoon Jang, Dong Hyeon Lee, Sae Kyung Joo, Bo Kyung Koo, Qiang Xia, Meng Sha, Yoosoo Chang, Won Kim Clinical Gastroenterology and Hepatology.2025; 23(13): 2540. CrossRef
Projected Trends in Metabolic Dysfunction–Associated Steatotic Liver Disease Mortality Through 2040 Xinrong Zhang, Sovann Linden, Charles R. Levesley, Xinyuan He, Zhanpeng Yang, Scott D. Barnet, Ramsey Cheung, Fanpu Ji, Mindie H. Nguyen JAMA Network Open.2025; 8(6): e2516367. CrossRef
Targeting MASLD and MASH in the US Hispanic/Latino Population Nicholas A. Cumpian, Julio A. Gutierrez, William Wu, Sammy Saab JAMA Internal Medicine.2025; 185(11): 1376. CrossRef
Metabolic dysfunction-associated steatotic liver disease in Egypt: Epidemiology, risk factors and management challenges Walaa Abdelhamed, Mona Amin, Imam Waked, Mohamed El-Kassas World Journal of Gastroenterology.2025;[Epub] CrossRef
Sex and Race-Ethnic Disparities in Metabolic Dysfunction-Associated Steatotic Liver Disease: An Analysis of 40,166 Individuals Clarissa Elysia Fu, Margaret Teng, Daniel Tung, Vijay Ramadoss, Christen Ong, Benjamin Koh, Wen Hui Lim, Darren Jun Hao Tan, Jia Hong Koh, Benjamin Nah, Nicholas Syn, Nobuharu Tamaki, Mohammad Shadab Siddiqui, Karn Wijarnpreecha, George N. Ioannou, Atsush Digestive Diseases and Sciences.2024; 69(9): 3195. CrossRef
Intervening on Metabolic Dysfunction-Associated Steatotic Liver Disease in Latino/a and Black Patients with Diabetes: A Feasibility Pilot Anastasia-Stefania Alexopoulos, Susanne Danus, Alice Parish, Maren K. Olsen, Bryan C. Batch, Connie R. Thacker, Cynthia A. Moylan, Matthew J. Crowley Diabetes Therapy.2024; 15(11): 2417. CrossRef
Metabolic Dysfunction-Associated Steatotic Liver Disease Is Associated with Increased Risk of Kidney Cancer: A Nationwide Study Juyeon Oh, Beom Kyung Kim, Jin-Ha Yoon, Hyung Ho Lee, Heejoo Park, Jian Lee, Youngsun Park, Byungyoon Yun, Jinsoo Chung Cancers.2024; 16(18): 3161. CrossRef
Prevalence and Characteristics of Metabolic Dysfunction-Associated Fatty Liver Disease among an Iranian Adult Population with Ethnic and Genetic Diversity: Results of the PolyIran-Liver Study Elham Jafari, Shahin Merat, Amir Anoushiravani, Amir Reza Radmard, Gholamreza Roshandel, Maryam Sharafkhah, Masoud Khoshnia, Alireza Nateghi, Abolfazl Shiravi Khuzani, Hossein Poustchi, Reza Malekzadeh Middle East Journal of Digestive Diseases.2024; 16(2): 86. CrossRef
Disparities in Heart Failure Deaths among Patients with Cirrhosis Benjamin Grobman, Arian Mansur, Christine Y. Lu Journal of Clinical Medicine.2024; 13(20): 6153. CrossRef
Racial and ethnic disparities in metabolic dysfunction-associated steatotic liver disease outcomes: A call for culturally sensitive interventions: Editorial on “Differences in liver and mortality outcomes of non-alcoholic fatty liver disease by race and e Jae Hyun Bae Clinical and Molecular Hepatology.2024; 30(4): 665. CrossRef
Differences in major adverse cardiovascular events of metabolic dysfunction-associated steatotic liver disease by race and ethnicity: Letter to the editor on “Differences in liver and mortality outcomes of non-alcoholic fatty liver disease by race and eth Hui-Chin Chang, Wen-Chieh Liao, Yi-Jen Fang, Shiu-Jau Chen, Shuo-Yan Gau Clinical and Molecular Hepatology.2024; 30(4): 978. CrossRef
Reply to correspondence on “Differences in liver and mortality outcomes of non-alcoholic fatty liver disease by race and ethnicity: A longitudinal real-world study” Jae Hyun Bae Clinical and Molecular Hepatology.2024; 30(4): 1047. CrossRef
Correspondence to editorial on “Differences in liver and mortality outcomes of non-alcoholic fatty liver disease by race and ethnicity: A longitudinal real-world study” Vy H. Nguyen, Mindie H. Nguyen Clinical and Molecular Hepatology.2024; 30(4): 1000. CrossRef
First
Prev
